Study S000281

Comparison of the Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Obese Patients With Kidney Disease: a Single Center, Prospective, Exploratory Study

ClinicalTrials.gov record

Registration

Registration: NCT06344247
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 48
Start: 2023-09-01
Primary completion: 2025-09-01
Lead sponsor: RenJi Hospital
Conditions: Obesity; Chronic Kidney Diseases
Interventions: DRUG:RAS inhibitors：Losartan®️/Valsartan®️; DRUG:dapagliflozin：Forxiga®️; DRUG:simagliptin：Forxiga®️
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change of 24-hour urine protein quantification [4、12、24、36、48 WEEK]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.